PRAMOMOLECULAR hat dies direkt geteilt
The clinical-stage startup Pioneera Biosciences from Dubai in the United Arab Emirates, and the preclinical startup PRAMOMOLECULAR from Berlin in Germany, want to fight cancer together. Despite all the progress made in cancer treatment, there is still a great medical need in oncology, as one in six people worldwide still dies of cancer. "Cancer cells are insidious enemies," emphasizes Alireza Daneshvar, founder and CEO of Pioneera, "they are constantly changing and thus evade monotherapies. We will therefore fight cancer in two different ways: Pioneera is activating the human immune system to attack oncogenic cells with its own weapons and PRAMO is downregulating the cancer protein to induce apoptosis.”Alireza Daneshvar was recently honored by Forbes magazine Middle East as one of the 30 under 30 2024. Pioneera's state-of-the-art proprietary platform (Discovery 4.0), supported by Artificial Intelligence and Machine Learning enables the optimization of processes and the design of therapeutics. This allows Pioneera to develop revolutionary Immunotherapeutics for oncology especially Next Generation CAR-T (Chimeric Antigen Receptor T-cell) and CAR-NK Therapies (Chimeric Antigen Receptor Natural Killer cell). CAR-T involves modifying a patient's T-cells to express a chimeric antigen receptor, enabling them to target and destroy cancer cells. Similarly, CAR-NK cells are Natural Killer cells engineered with a chimeric receptor for targeted cancer cell killing. PRAMOMOLECULAR, recently honored by Falling Walls Foundation as one of eight Health Startups worldwide, is developing gene silencing drug candidates against different oncoproteins like the RAS oncoproteins – the most important oncogenic drivers in humans. "Through a combination of our proprietary delivery platform, rational design, in silico optimization, automated manufacturing and highly informative in vivo disease models, we at PRAMO are able to identify fast well-tolerated drug candidates to down-regulate the most important cancer proteins: No cancer protein – no cancer," emphasizes Ida Shaef, Chief Scientific Officer of PRAMOMOLECULAR. Both drug developers have a mutual interest in working together to develop therapies more efficiently and well tolerated. Above all, this includes utilizing opportunities for cooperation in the preclinical and clinical development of co-therapies to enhance the effects of immunotherapies and gene silencing and reduce side effects. "We are not only utilizing the complementary advantages of our therapeutic approaches, but also the advantages of our different locations and networks on two continents: broader access to knowledge, experts, infrastructure, capital and patients," adds Merle Fuchs, CEO of PRAMOMOLECULAR. "We are aware that disruptive advances arise above all where different technologies, corporate cultures and ways of thinking come together. This potential must be used to help terminally ill people."